HC Wainwright reiterates the Buy rating on Spectrum Pharmaceuticals Inc (NASDAQ: SPPI), with a price target of $10.
The analyst projects revenues of $170 million for Rolontis and $328 million for poziotinib in 2026.
Eflapegrastim (formerly known as Rolontis; to be renamed) is a long-acting granulocyte colony-stimulating factor intended to stimulate neutrophil production for chemotherapy-induced neutropenia patients.
Spectrum resubmitted the BLA for eflapegrastim to the FDA for review. Eflapegrastim's BLA previously received a CRL citing deficiencies in manufacturing at the drug manufacturing plant in South Korea.
Related: Spectrum Pharma Highlights Poziotinib Data In Treatment-Naïve Lung Cancer Setting.
The manufacturing plant in South Korea still needs to be reinspected, and notes the BLA resubmission could lead to a PDFUA date in September 2022.
HC Wainwright anticipates a launch for eflapegrastim in late-2022 with $5 million in sales in 2022, growing to $170 million in 2026.
Spectrum reported a 4Q FY21 adjusted EPS loss of $(0.17), beating the consensus of $(0.21).
Spectrum reported cash, cash equivalents, and marketable securities of approximately $100.6 million. The additional cash, combined with the restructuring, is expected to extend the Company's cash runway into 2023.
Price Action: SPPI shares are up 8.98% at $0.93 during the market session on the last check Friday.
Latest Ratings for SPPI
View More Analyst Ratings for SPPI
View the Latest Analyst Ratings
See more from Benzinga
Spectrum Pharma Highlights Poziotinib Data In Treatment-Naïve Lung Cancer Setting
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
